Objective  To explore the efficacy and safety of aprepitant in preventing nausea and vomiting due to chemotherapy for breast cancer.

  Methods  Totally 100 patients with breast cancer were randomly divided into observation group (n=50) and control group (n=50). The control group was given dexamethasone combined with tropisetron, while the observation group was given aprepitant on the basis of the control group. Efficacy and adverse reactions of preventive therapy for nausea and vomiting caused by chemotherapy were compared, and qualities of life in patients were evaluated.

  Results  In the observation group, the incidence rate of delayed nausea and vomiting was significantly lower than that in the control group, while the ratio of patients without nausea and vomiting symptoms, the effective rate of treatment for nausea and vomiting and the score of quality of life after chemotherapy were significantly higher than those in the control group (P < 0.05). There were no significant differences in the incidence rates of dizziness, liver dysfunction, anorexia, fatigue and constipation between the two groups after chemotherapy (P>0.05).

  Conclusion  Aprepitant can effectively prevent nausea and vomiting caused by chemotherapy for breast cancer, improve patients'quality of life, and its safety is relatively high.